{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,20]],"date-time":"2025-12-20T22:06:48Z","timestamp":1766268408449,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1016\/j.clgc.2023.03.002","type":"journal-article","created":{"date-parts":[[2023,3,17]],"date-time":"2023-03-17T03:37:48Z","timestamp":1679024268000},"page":"e286-e290","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Sequential Treatment With Bacillus Calmette-G\u00fcerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure"],"prefix":"10.1016","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4306-7710","authenticated-orcid":false,"given":"Isabel","family":"Sanz G\u00f3mez","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Huguet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alejandra","family":"Bravo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Robalino","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00d3scar","family":"Rodr\u00edguez Faba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"\u00c1ngelo","family":"Territo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Josep Mar\u00eda","family":"Gaya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joan","family":"Palou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto","family":"Breda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2023.03.002_bib0001","doi-asserted-by":"crossref","first-page":"204","DOI":"10.5489\/cuaj.6101","article-title":"Emerging intravesical therapies for the management of bacillus Calmette\u2013Gu\u00e9rin (BCG)-unresponsive non-muscle-invasive bladder cancer: charting a path forward","volume":"14","author":"Chehroudi","year":"2020","journal-title":"Can Urol Assoc J"},{"key":"10.1016\/j.clgc.2023.03.002_bib0002","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1586\/era.09.35","article-title":"Definition and management of patients with bladder cancer who fail BCG therapy","volume":"9","author":"Martin","year":"2009","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.clgc.2023.03.002_bib0003","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1038\/nrurol.2017.16","article-title":"BCG-unresponsive non-muscle-invasive bladder cancer: recommendations from the IBCG","volume":"14","author":"Kamat","year":"2017","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0004","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1097\/JU.0000000000000919","article-title":"A phase I trial of intravesical cabazitaxel, gemcitabine and cisplatin for the treatment of nonmuscle invasive bacillus Calmette-Gu\u00e9rin unresponsive or recurrent\/relapsing urothelial carcinoma of the bladder","volume":"204","author":"DeCastro","year":"2020","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0005","doi-asserted-by":"crossref","first-page":"850.e9","DOI":"10.1016\/j.urolonc.2020.06.031","article-title":"Sequential administration of Bacillus Calmette-Guerin (BCG) and Electromotive Drug Administration (EMDA) of mitomycin C (MMC) for the treatment of high-grade nonmuscle invasive bladder cancer after BCG failure","volume":"38","author":"Juvet","year":"2020","journal-title":"Urol Oncol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1186\/s12885-018-5134-7","article-title":"ElectroMotive drug administration (EMDA) of Mitomycin C as first-line salvage therapy in high risk \u201cBCG failure\u201d non muscle invasive bladder cancer: 3 years follow-up outcomes","volume":"18","author":"Racioppi","year":"2018","journal-title":"BMC Cancer"},{"key":"10.1016\/j.clgc.2023.03.002_bib0007","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/S0090-4295(97)00625-0","article-title":"Intravesical electromotive administration of drugs for treatment of superficial bladder cancer: a comparative phase II study","volume":"51","author":"Brausi","year":"1998","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2023.03.002_bib0008","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1002\/jps.2600780502","article-title":"Iontophoretic (transdermal) delivery of drugs: overview of historical development","volume":"78","author":"Chien","year":"1989","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clgc.2023.03.002_bib0009","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0010","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.eururo.2021.08.010","article-title":"European Association of Urology guidelines on non-muscle-invasive bladder cancer (Ta, T1, and carcinoma in situ)","volume":"81","author":"Comp\u00e9rat","year":"2022","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0011","doi-asserted-by":"crossref","first-page":"1935","DOI":"10.1200\/JCO.2015.64.4070","article-title":"Definitions, end points, and clinical trial designs for non\u2013muscle-invasive bladder cancer: recommendations from the international bladder cancer group","volume":"34","author":"Kamat","year":"2016","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0012","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of Bacillus Calmette-Guerin refractory carcinoma in situ of the bladder. The Valrubicin Study Group","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0013","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S1470-2045(21)00147-9","article-title":"Pembrolizumab monotherapy for the treatment of high-risk non-muscle-invasive bladder cancer unresponsive to BCG (KEYNOTE-057): an open-label, single-arm, multicentre, phase 2 study","volume":"22","author":"v","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0014","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0015","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of Oportuzumab Monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Gu\u00e9rin","volume":"188","author":"Kowalski","year":"2012","journal-title":"J Urol"},{"key":"10.1016\/j.clgc.2023.03.002_bib0016","doi-asserted-by":"crossref","first-page":"902","DOI":"10.1097\/JU.0000000000000688","article-title":"Multi-institution evaluation of sequential gemcitabine and docetaxel as rescue therapy for nonmuscle invasive bladder cancer","volume":"203","author":"Steinberg","year":"2020","journal-title":"J Urol"},{"issue":"62","key":"10.1016\/j.clgc.2023.03.002_bib0017","first-page":"e13","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"Pijpers","year":"2022","journal-title":"Urol Oncol"}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000617?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767323000617?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:19Z","timestamp":1761564979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767323000617"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":17,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["S1558767323000617"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.002","relation":{},"ISSN":["1558-7673"],"issn-type":[{"type":"print","value":"1558-7673"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Sequential Treatment With Bacillus Calmette-G\u00fcerin (BCG) and Mitomycin C Administered With Electromotive Drug Administration (EMDA) in Patients With High-Risk Nonmuscle Invasive Bladder Cancer After BCG Failure","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2023.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}